Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40J6W | ISIN: US2062772049 | Ticker-Symbol: C2C
NASDAQ
11.11.24
21:58 Uhr
5,130 US-Dollar
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
CONCORD MEDICAL SERVICES HOLDINGS LTD ADR Chart 1 Jahr
5-Tage-Chart
CONCORD MEDICAL SERVICES HOLDINGS LTD ADR 5-Tage-Chart
PR Newswire
301 Leser
Artikel bewerten:
(2)

Concord Medical Services Holdings Limited: Concord Medical Reports Financial Results for the First Half of 2024

Finanznachrichten News

BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].

2024 First Half Highlights

  • Total net revenues were RMB218.8 million (US$30.1 million) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million (US$19.0 million) and the net revenues from the network business of RMB81.0 million (US$11.1 million).
  • Gross loss was RMB41.6 million (US$5.7 million) in the first half of 2024, compared to the gross loss of RMB37.4 million in the first half of 2023. The gross loss margin was 19.0% for the first half of 2024, compared to 13.2% for the same period last year.
  • Net loss attributable to ordinary shareholders in the first half of 2024 was RMB172.3 million (US$23.7 million), compared to RMB91.0 million in the same period last year.
  • Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31 (US$0.18), compared to RMB0.69 in the same period last year.
  • Non-GAAP[2] net loss in the first half of 2024 was RMB328.7 million (US$45.2 million), compared to non-GAAP net loss of RMB210.3 million in the same period last year. Non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31 (US$0.18), compared to RMB0.69 in the same period last year.
  • Adjusted EBITDA[3] (non-GAAP) was negative RMB148.0 million (US$20.4 million) in the first half of 2024, compared to negative RMB148.4 million in the same period last year.

[1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.2672 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 28, 2024.

[2] Non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares are defined as their most directly comparable GAAP measures excluding the impact of share-based compensation expenses.

[3] Adjusted EBITDA is defined as net income/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "In the past few years, Concord Medical has been actively building a solid foundation for its business development, as well as looking to the future by profoundly enhancing its expertise in oncology care and strengthening the competitiveness of its international diagnosis and treatment services. Concurrently, Concord Medical has been continually exploring the untapped potential of its network business, striving for growth and expansion.

We are delighted to announce that, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of our Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license for its proton equipment, as announced by the National Health Commission of the PRC on September 14, 2024. Proton therapy services stand as a pivotal segment within Concord Medical's hospital business, anticipated to deliver a significant boost to our revenue base upon its successful implementation. This endeavor will concurrently elevate Guangzhou Hospital's profile and reputation. Looking ahead, we maintain a positive outlook on the growth potential of this sector, expecting continued development and expansion through 2025 and beyond."

2024 First Half Financial Results

Net Revenues

Hospital Business

Net revenues from the hospital business were RMB137.8 million (US$19.0 million) in the first half of 2024, representing a 13.2% decrease from net revenues of RMB158.7 million in the first half of 2023, mainly because (1) we downsized certain of our hospital business with lower profit margin, and (2) as we concentrated the resources in preparing our proton therapy business, the revenue from the medical institutions fluctuated in the short term.

Network Business

Net revenues from the network business were RMB81.0 million (US$11.1 million), representing a 35.6% decrease from net revenues of RMB125.8 million in the first half of 2023, mainly because of the decreased demand for medical equipment, software and the relevant management and technical support services by our customers in current economic environment.

Cost of Revenues

Hospital Business

Cost of revenues of the hospital business in the first half of 2024 was RMB174.0 million (US$23.9 million), representing a 14.9% decrease from cost of revenues of RMB204.4 million in the first half of 2023, mainly because of (1) our overall efforts to improve operation efficiency and reduce costs, especially for staff costs, and (2) the decrease of consumables and maintenance cost, lease cost and staff cost along with the fluctuation in hospital business.

Network Business

Cost of revenues of the network business was RMB86.4 million (US$11.9 million), representing a 26.4% decrease from RMB117.5 million in the first half of 2023, generally in line with the decrease in the business scale and revenue generated from sales and installation of medical equipment and software, management and technical support services.

Gross Loss and Gross Loss Margin

Hospital Business

Gross loss from the hospital business was RMB36.2 million (US$4.9 million) in the first half of 2024, compared to RMB45.7 million in the same period last year. The gross loss margin of the hospital business for the first half of 2024 was 26.3%, compared to the gross loss margin of 28.8% for the same period last year. The improvement in gross loss margin of the hospital business was primarily because of our overall efforts to improve operation efficiency and reduce costs.

Network Business

Gross loss from the network business was RMB5.4 million (US$0.8 million), compared to the gross profit of RMB8.3 million in the first half of 2023. The gross loss margin of the network business for the first half of 2024 was 6.7%, relatively stable compared to the gross profit margin of 6.6% for the same period last year.

Operating Expenses

Selling expenses were RMB25.0 million (US$3.4 million) in the first half of 2024, compared to RMB26.4 million in the first half of 2023. Selling expenses as a percentage of net revenues was 11.4% in the first half of 2024, compared to 9.3% in the first half of 2023.

General and administrative expenses were RMB131.2 million (US$18.1 million) in the first half of 2024, of which employee benefit expenses were RMB62.4 million (US$8.6 million). In the same period of last year, general and administrative expenses were RMB150.2 million. The decrease was mainly attributable to the decrease in staff cost and our overall efforts to improve operation efficiency. General and administrative expenses as a percentage of net revenues was 59.9% in the first half of 2024, compared to 52.8% in the first half of 2023.

Capital Expenditures

Comparing to RMB46.5 million in the first half of 2023, capital expenditures were RMB168.4 million (US$23.2 million) in the first half of 2024, mainly due to the increase in deposit for non-current assets and construction fees for our hospital business.

Accounts Receivable

As of June 30, 2024, accounts receivable were RMB78.2 million (US$10.8 million), representing a 6.4% increase from accounts receivable of RMB73.5 million as of December 31, 2023. The average period of sales outstanding for accounts receivable (also known as days sales outstanding) was 171 days in the first half of 2024.

Bank Loans and Other Borrowings

As of June 30, 2024, the Company had bank loans and other borrowings totaling RMB3.4 billion (US$463.6 million).

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expenses, such as non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares. The Company believes excluding share-based compensation expenses from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results, as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expenses are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Concord Medical Services Holdings Co., Ltd.


Consolidated Balance Sheets
(in thousands)





December 31,





2023


June 30, 2024



RMB


RMB


US$



(Audited)


(Unaudited)


(Unaudited)


ASSETS







Current assets







Cash and cash equivalents

58,139


115,667


15,916


Short-term investment

-


211,238


29,067


Restricted cash, current portion

32,280


10,116


1,392


Accounts receivable, net

73,496


78,222


10,764


Prepayments and other current assets, net

412,946


574,330


79,030


Inventories

40,347


39,832


5,481


Total current assets

617,208


1,029,405


141,650


Non-current assets







Property, plant and equipment, net

3,546,873


3,555,860


489,303


Right-of-use assets, net

580,365


538,514


74,102


Goodwill

575,427


572,216


78,740


Intangible assets, net

323,287


300,569


41,360


Deposits for non-current assets

4,646


139,085


19,139


Long-term investments

394,711


480,873


66,170


Other non-current assets

11,426


6,171


849


Total non-current assets

5,436,735


5,593,288


769,663









Total assets

6,053,943


6,622,693


911,313


LIABILITIES AND EQUITY







Current liabilities







Accounts payable

129,236


127,334


17,522


Accrued expenses and other liabilities

731,793


740,827


101,940


Income tax payable

1,522


1,581


218


Operating lease liabilities, current

46,492


35,700


4,912


Short-term bank and other borrowings

319,625


363,446


50,012


Long-term bank and other borrowings, current portion

722,563


793,760


109,225


Derivative liability

163


109,632


15,086


Total current liabilities

1,951,394


2,172,280


298,915


Non-current liabilities







Long-term bank and other borrowings, non-current portion

1,994,014


2,211,862


304,362


Deferred tax liabilities

99,538


92,807


12,771


Operating lease liabilities, non-current

193,007


159,461


21,943


Other long-term liabilities

69,003


65,397


9,000


Total non-current liabilities

2,355,562


2,529,527


348,076


Total liabilities

4,306,956


4,701,807


646,991


EQUITY







Class A ordinary shares

68


68


9


Class B ordinary shares

37


37


5


Treasury stock

(7)


(7)


(1)


Additional paid-in capital

2,007,965


2,169,695


298,560


Accumulated other comprehensive loss

(65,419)


(71,694)


(9,865)


Accumulated deficit

(4,064,589)


(4,236,847)


(583,010)


Total Concord Medical Services Holdings Limited shareholders' deficit

(2,121,945)


(2,138,748)


(294,302)


Noncontrolling interests

3,868,932


4,059,634


558,624









Total equity

1,746,987


1,920,886


264,322









Total liabilities and equity

6,053,943


6,622,693


911,313


Concord Medical Services Holdings Co., Ltd.

Consolidated Profit & Loss

(in thousands, except for number of shares and per share data)



June 30,
202
3


June 30, 2024


RMB


RMB


US$


(Unaudited)


(Unaudited)


(Unaudited)

Revenues, net of business tax, value-added tax and related
surcharges






Hospital

158,707


137,772


18,958

Network

125,806


81,038


11,151

Total net revenues

284,513


218,810


30,109

Cost of revenues:






Hospital

(204,433)


(173,963)


(23,938)

Network

(117,503)


(86,443)


(11,895)

Total cost of revenues

(321,936)


(260,406)


(35,833)







Gross loss

(37,423)


(41,596)


(5,724)







Operating expenses:






Selling expenses

(26,362)


(24,975)


(3,437)

General and administrative expenses

(150,240)


(131,173)


(18,050)







Operating loss

(214,025)


(197,744)


(27,211)

Interest expense

(84,374)


(68,668)


(9,449)

Foreign exchange loss, net

(2,444)


(30,269)


(4,165)

Gain on disposal of long-lived equipment

62


-


-

Interest income

5,800


5,990


824

Change in fair value of derivative liability

-


(108,777)


(14,968)

Income from equity method investments

10,099


6,070


835

Gain on disposal of subsidiaries

-


47,997


6,605

Other income, net

13,623


1,388


191

Gain on disposal of equity method investment

37,498


-


-

Changes in fair value of short-term investments

-


6,631


912







Loss before income tax

(233,761)


(337,382)


(46,426)

Income tax expenses

23,417


8,674


1,194

Net loss

(210,344)


(328,708)


(45,232)







Net loss attributable to noncontrolling interests

(119,359)


(156,450)


(21,528)

Net loss attributable to Concord Medical Services Holdings
Limited

(90,985)


(172,258)


(23,704)







Loss per share for Class A and Class B ordinary shares






Basic

(0.69)


(1.31)


(0.18)

Diluted

(0.69)


(1.31)


(0.18)







Weighted average number of class A and class B ordinary shares
outstanding:






Basic

131,053,858


131,053,858


131,053,858

Diluted

131,053,858


131,053,858


131,053,858

Other comprehensive loss, net of tax of nil






Foreign currency translation, net of tax of nil

(17,371)


(6,273)


(863)

Total other comprehensive loss, net of tax

(17,371)


(6,273)


(863)

Comprehensive loss

(227,715)


(334,981)


(46,095)

Comprehensive loss attributable to noncontrolling interests

(119,359)


(156,450)


(21,528)

Comprehensive loss attributable to Concord Medical Services
Holdings Limited's shareholders

(108,356)


(178,531)


(24,567)

Reconciliations of non-GAAP results of operations measures to the
nearest comparable GAAP measures

(in RMB thousands, except per share data unaudited)




For the six months ended


For the six months ended



June 30, 2023


June 30, 2024







Non-






Non-



GAAP




GAAP


GAAP




GAAP



Measure


Adjustment


Measure


Measure


Adjustment


Measure

Operating loss


(214,025)


-


(214,025)


(197,744)


-


(197,744)

Net loss


(210,344)


-


(210,344)


(328,708)


-


(328,708)

Basic loss per share for
Class A and

Class B ordinary
shares


(0.69)


-


(0.69)


(1.31)


-


(1.31)

Diluted loss per share
for Class A and

Class B ordinary
shares


(0.69)


-


(0.69)


(1.31)


-


(1.31)














Reconciliation from net income to adjusted EBITDA(*) (in RMB
thousands, unaudited)



For the six months ended


For the six months ended


June 30, 2023


June 30, 2024

Net loss

(210,344)


(328,708)

Interest expenses, net

78,574


62,678

Income tax expenses

(23,417)


(8,674)

Depreciation and amortization

55,537


43,654

Share-based compensation

-


-

Other adjustments

(48,739)


83,030

Adjusted EBITDA

(148,389)


(148,020)

EBITDA margin

-52 %


-68 %


(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income tax expenses,
depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign
exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair
value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.

SOURCE Concord Medical Services Holdings Limited

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.